Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Gross Margin (2025)

Historic Gross Margin for ImmunityBio (IBRX) over the last 3 years, with Q3 2025 value amounting to 99.45%.

  • ImmunityBio's Gross Margin fell 5500.0% to 99.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 99.55%, marking a year-over-year decrease of 4500.0%. This contributed to the annual value of 100.0% for FY2024, which is 0.0% changed from last year.
  • Per ImmunityBio's latest filing, its Gross Margin stood at 99.45% for Q3 2025, which was down 5500.0% from 99.49% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Gross Margin registered a high of 100.0% during Q2 2023, and its lowest value of 99.45% during Q3 2025.
  • Its 3-year average for Gross Margin is 99.86%, with a median of 100.0% in 2023.
  • As far as peak fluctuations go, ImmunityBio's Gross Margin changed by 0bps in 2024, and later crashed by -5500bps in 2025.
  • Quarter analysis of 3 years shows ImmunityBio's Gross Margin stood at 100.0% in 2023, then changed by 0bps to 100.0% in 2024, then fell by -1bps to 99.45% in 2025.
  • Its last three reported values are 99.45% in Q3 2025, 99.49% for Q2 2025, and 99.65% during Q1 2025.